Last updated: February 12, 2026
What Is the Market Status and Price Projection for NDC 60505-0042?
NDC 60505-0042 corresponds to Voxzogo (vosoritide), developed by BioMarin Pharmaceutical. It targets achondroplasia, a form of dwarfism. Since FDA approval in July 2021, the drug's market position and pricing strategies have evolved accordingly.
Market Landscape and Competitive Position
Regulatory and Clinical Overview
- FDA Approval: July 2021.
- Indications: Treatment of achondroplasia in pediatric patients age 2 years and older.
- Clinical Status: Driven primarily by targeted therapy in the rare disease segment.
Key Competitors and Market Dynamics
- Existing Treatments: No approved disease-modifying therapies for achondroplasia before Voxzogo. Previous management relied on supportive therapies.
- Emerging Drugs: Limited competitors exist; however, ongoing clinical trials target similar pathways or aim for gene-based therapies, potentially influencing future market share.
Market Adoption and Prescriptions
- Initial Launch: Focused on specialized centers; slow uptake attributed to the rarity of condition and high costs.
- Insurance and Reimbursement: Coverage is a critical factor influencing accessibility; health insurers typically require evidence of clinical benefit.
- Physician Adoption: Centers specializing in genetic and pediatric endocrinology contribute most to initial prescriptions.
Market Size Estimation
- Prevalence: Approximately 1 in 15,000 to 40,000 live births worldwide.
- US Population with Achondroplasia: Estimated at 1,500 to 2,000 children.
- Potential Patient Pool: Limited by age and diagnosis rate; actual treated patients depend on diagnosis rates and reimbursement.
Price Strategy and Projections
Current Price Point
- List Price: Approximately $127,000 per year per patient in the US (Biopharma industry estimates, as of 2022).
- Pricing Rationale: Reflects the rarity, manufacturing costs, and targeted therapy status.
Reimbursement and Net Price
- Reimbursement Trends: Insurers typically negotiate discounts of 20-30% off list price.
- Net Price: Estimated at roughly $89,000 to $101,000 annually per patient depending on contractual terms.
Future Price Trends
| Factor |
Impact |
Projection |
| Policy Changes |
Potential Medicaid and insurance pressure |
Possible price reductions of 10-15% over 3-5 years |
| Market Expansion |
Approval for broader age groups or indications |
Slight price increment linked to additional value demonstration |
| Competition |
Entry of alternative therapies |
Probability of price stabilization or slight decline within 3-7 years |
Revenue Projections
- Year 1 (2023-2024): 150-200 patients treated in the US, generating approximately $13 million to $20 million in gross revenue.
- Long-Term (2025+): With market growth and potential approval overseas, revenues could reach $50-100 million annually by 2030.
Key Factors Influencing Price and Market Growth
- Clinical Outcomes: Demonstration of long-term benefit influences payer confidence.
- Pricing Pressure: Payer negotiations may limit annual increases.
- Market Penetration: Physician awareness and diagnosis rates determine accessible patient base.
- Regulatory Decisions: Expansion for broader age groups or indications can expand market size.
Key Takeaways
- Voxzogo (vosoritide) has a limited but growing market primarily driven by rare disease treatment dynamics.
- US list price is approximately $127,000 annually, with net prices around 20-30% lower after discounts.
- The initial market size is small, with approximately 1,500-2,000 potential pediatric patients in the US.
- Market growth depends heavily on insurance reimbursement, physician adoption, and regulatory expansions.
- Price adjustments are likely within 10-15% over the next 3-5 years, influenced by competition and policy changes.
FAQs
1. What factors could significantly alter the price of Voxzogo?
Insurance reimbursement policies and potential entry of alternative therapies could reduce prices. Regulatory approval for broader populations or additional indications might increase demand, supporting higher prices.
2. How does the rarity of achondroplasia impact market growth?
Low prevalence limits large-scale sales, making niche pricing critical. Market expansion depends on diagnosis improvements and surgeon adoption rates.
3. What are the main barriers to wider adoption?
High treatment cost, limited awareness among general practitioners, and insurance coverage challenges restrict widespread adoption.
4. Could overseas markets significantly increase revenue?
Yes. Approval in Europe and other regions could double or triple potential patient access, provided pricing remains viable.
5. Are generic or biosimilar options expected for Voxzogo?
Soyarentous patents and exclusivity periods protect Voxzogo from biosimilars until 2030 or later. No biosimilar competition is currently anticipated in the short term.
Sources
[1] FDA Approval Announcement, 2021.
[2] BioMarin Pharmaceuticals Investor Presentation, 2023.
[3] Industry Reports on Rare Disease Drug Pricing, 2022.
[4] Market Research on Achondroplasia, 2023.
[5] Reimbursement Data from USDHHS, 2022.
